Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
about
Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies.The impact and treatment of obesity in kidney transplant candidates and recipientsUnited States Food and Drug Administration approved oral kinase inhibitors for the treatment of malignanciesThe effects of gastric bypass surgery on drug absorption and pharmacokinetics.The influence of bypass procedures and other anatomical changes in the gastrointestinal tract on the oral bioavailability of drugs.Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations.Contribution of ABCC4-mediated gastric transport to the absorption and efficacy of dasatinib.Developing an Agent-Based Drug Model to Investigate the Synergistic Effects of Drug Combinations.Lithium toxicity after Roux-en-Y bariatric surgery.Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.Clinical efficacy of generic imatinib
P2860
Q35115436-0AABEA33-F585-4D06-B8A4-6C8E1469B99DQ35908188-BBBA8371-2B8B-44C0-B063-E054316D0BBDQ37142970-ABAD8105-1235-446C-923F-8D3F562B892BQ38045375-7F9E81D0-F6F2-4E05-8D0E-FF445A91EBB6Q38079182-3B25DA5B-1DA2-4F05-A68E-5C8B2422B901Q38874008-5EB0CF2D-AB59-412F-9EA2-473B450F87F6Q41763725-90ECD976-E455-41D9-ACDF-E6F1EF2FAAE4Q47310421-467F8D17-EFEF-421C-B157-51A06199C485Q53144975-D603F6E8-7867-4468-AA6A-36D2A5B9A1CFQ54641441-843CC0CA-8050-499D-8C5D-B84397ADFD88Q57108016-07A58637-F93E-4431-B843-FBF7B7F08F96
P2860
Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Imatinib mesylate pharmacokine ...... with chronic myeloid leukemia.
@en
Imatinib mesylate pharmacokine ...... with chronic myeloid leukemia.
@nl
type
label
Imatinib mesylate pharmacokine ...... with chronic myeloid leukemia.
@en
Imatinib mesylate pharmacokine ...... with chronic myeloid leukemia.
@nl
prefLabel
Imatinib mesylate pharmacokine ...... with chronic myeloid leukemia.
@en
Imatinib mesylate pharmacokine ...... with chronic myeloid leukemia.
@nl
P2093
P2860
P921
P356
P1433
P1476
Imatinib mesylate pharmacokine ...... with chronic myeloid leukemia
@en
P2093
Carolina Pavlovsky
Dhvani D Shah
Merrill J Egorin
Santiago Pavlovsky
Silvia Rogel
P2860
P304
P356
10.1592/PHCO.29.9.1152
P407
P50
P577
2009-09-01T00:00:00Z